IPX066 145 mg ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01096186 (ClinicalTrials.gov)	March 2010	25/3/2010	An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease	An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: IPX066 95 mg;Drug: IPX066 145 mg;Drug: IPX066 195 mg;Drug: IPX066 245 mg	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	617	Phase 3	United States;Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine
2	NCT00880620 (ClinicalTrials.gov)	April 2009	3/4/2009	A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease	A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease	Parkinson's Disease	Drug: Placebo;Drug: IPX066 95 mg LD;Drug: IPX066 145 mg LD;Drug: IPX066 195 mg LD;Drug: IPX066 245 mg LD	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	381	Phase 3	United States;Canada;Estonia;Latvia;Lithuania;Romania;Ukraine